Literature DB >> 12060348

Apoptosis of astrocytes with enhanced lysosomal activity and oligodendrocytes in white matter lesions in Alzheimer's disease.

K Kobayashi1, M Hayashi, H Nakano, Y Fukutani, K Sasaki, M Shimazaki, Y Koshino.   

Abstract

Cerebral white matter lesions in Alzheimer's disease (AD) consist of subcortical degeneration and ischaemic-hypoxic changes. Glial changes are intimately associated with the white matter lesions, and regressive changes in astrocytes and loss of oligodendroglial cells have been reported. We quantitatively compared glial changes including apoptosis and enhanced lysosomal activity in the frontal and temporal white matter by using terminal dUTP nick end labelling (TUNEL) and immunohistochemistry for glial markers, lysosomes and apoptosis-regulating proteins in non-familial AD brains. The degree of myelin pallor and axonal loss varied considerably in both the frontal and temporal white matter but fibrillary gliosis in demyelinated lesions tended to be less prominent in the temporal white matter in AD cases. A morphometric study with planimetric methods for cross-sectional areas of frontal and temporal white matter revealed that the white matter of AD cases manifested atrophy with significant reduction in frontal (11.9%) and temporal (29.4%) white matter compared to normal controls. Double immunolabelling for glial fibrillary acidic protein (GFAP) and KP1 (CD68) revealed KP1-positive fragmented structures within the weakly GFAP-labelled astrocytes. These KP1-positive structures correspond to process fragmentation and cytoplasmic vacuoles, which in turn indicate enhanced lysosomal activity during regressive changes in astrocytes. The KP1-modified astrocytes were not found in Pick's disease and corticobasal degeneration. The density of apoptotic glial cells, largely oligodendroglial, was significantly higher in the temporal than in the frontal white matter, and most GFAP-positive astrocytes with regressive changes were apoptotic. GFAP-positive astrocyte density was statistically the same in the frontal and temporal white matter, but the density of KP1-modified astrocytes was higher in the temporal than in the frontal white matter. The rate of white matter shrinkage was significantly correlated with the density of apoptotic glial cells and the density of KP1-modified astrocytes in the temporal lobe in AD cases. An increase in apoptotic glial cell density was found to contribute to GFAP-positive astrocytes with regressive changes in temporal white matter, while apoptosis of vascular smooth muscle cells did not show topographical accentuation. Astrocytes labelled with beta amyloid protein were not apoptotic, and the density of apoptotic cells labelled with CD95 and caspase-3 was too low in both types of white matter to be statistically evaluated. Our results imply that regressive changes in astrocytes and glial apoptosis are, to some extent, associated with white matter lesions, particularly of the temporal lobe in AD brains. The presence of apoptotic astrocytes with evidence of regressive change could therefore be a histological hallmark for white matter degeneration in AD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12060348     DOI: 10.1046/j.1365-2990.2002.00390.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  27 in total

1.  Characterization of AD-like phenotype in aged APPSwe/PS1dE9 mice.

Authors:  Huang Huang; Sipei Nie; Min Cao; Charles Marshall; Junying Gao; Na Xiao; Gang Hu; Ming Xiao
Journal:  Age (Dordr)       Date:  2016-07-21

2.  Astrocytes secrete exosomes enriched with proapoptotic ceramide and prostate apoptosis response 4 (PAR-4): potential mechanism of apoptosis induction in Alzheimer disease (AD).

Authors:  Guanghu Wang; Michael Dinkins; Qian He; Gu Zhu; Christophe Poirier; Andrew Campbell; Margot Mayer-Proschel; Erhard Bieberich
Journal:  J Biol Chem       Date:  2012-04-24       Impact factor: 5.157

3.  Decreased oligodendrocyte nuclear diameter in Alzheimer's disease and Lewy body dementia.

Authors:  Eva Gagyi; Bernadett Kormos; Karla J Castellanos; Klara Valyi-Nagy; Dennis Korneff; Patrizia LoPresti; Randy Woltjer; Tibor Valyi-Nagy
Journal:  Brain Pathol       Date:  2012-04-12       Impact factor: 6.508

4.  TNF alpha affects the expression of GFAP and S100B: implications for Alzheimer's disease.

Authors:  M M Edwards; S R Robinson
Journal:  J Neural Transm (Vienna)       Date:  2006-06-01       Impact factor: 3.575

5.  Neuroprotective effects of astragaloside IV on Parkinson disease models of mice and primary astrocytes.

Authors:  Lei Xia; Dianxuan Guo; Bing Chen
Journal:  Exp Ther Med       Date:  2017-09-29       Impact factor: 2.447

6.  Caspase-mediated cleavage of glial fibrillary acidic protein within degenerating astrocytes of the Alzheimer's disease brain.

Authors:  Peter E Mouser; Elizabeth Head; Kwang-Ho Ha; Troy T Rohn
Journal:  Am J Pathol       Date:  2006-03       Impact factor: 4.307

7.  Resveratrol Protects Optic Nerve Head Astrocytes from Oxidative Stress-Induced Cell Death by Preventing Caspase-3 Activation, Tau Dephosphorylation at Ser422 and Formation of Misfolded Protein Aggregates.

Authors:  John C Means; Adam A Lopez; Peter Koulen
Journal:  Cell Mol Neurobiol       Date:  2020-01-09       Impact factor: 5.046

Review 8.  Modeling Alzheimer's disease with human induced pluripotent stem (iPS) cells.

Authors:  Alison E Mungenast; Sandra Siegert; Li-Huei Tsai
Journal:  Mol Cell Neurosci       Date:  2015-12-04       Impact factor: 4.314

9.  Uncovering molecular biomarkers that correlate cognitive decline with the changes of hippocampus' gene expression profiles in Alzheimer's disease.

Authors:  Martín Gómez Ravetti; Osvaldo A Rosso; Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2010-04-13       Impact factor: 3.240

10.  Evidence of DNA damage in Alzheimer disease: phosphorylation of histone H2AX in astrocytes.

Authors:  Na-Hye Myung; Xiongwei Zhu; Inna I Kruman; Rudy J Castellani; Robert B Petersen; Sandra L Siedlak; George Perry; Mark A Smith; Hyoung-gon Lee
Journal:  Age (Dordr)       Date:  2008-04-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.